NCT03633279 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Dasarathy S, Merli M
Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016 Dec;65(6):1232-1244. doi: 10.1016/j.jhep.2016.07.040. Epub 2016 Aug 8.
Kim G, Kang SH, Kim MY, Baik SK
Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS One. 2017 Oct 24;12(10):e0186990. doi: 10.1371/journal.pone.0186990. eCollection 2017.
Kim HY, Jang JW
Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. World J Gastroenterol. 2015 Jul 7;21(25):7637-47. doi: 10.3748/wjg.v21.i25.7637.
Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, Ridola L, Attili AF, Venditti M
Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol. 2010 Nov;8(11):979-85. doi: 10.1016/j.cgh.2010.06.0
Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, Sawyer MB
Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012 Feb;10(2):166-73, 173.e1. doi: 10.1016/j.cgh.2011.08.028. Epub 2
Roubenoff R
Sarcopenia: effects on body composition and function. J Gerontol A Biol Sci Med Sci. 2003 Nov;58(11):1012-7. doi: 10.1093/gerona/58.11.m1012.
Wilson D, Jackson T, Sapey E, Lord JM
Frailty and sarcopenia: The potential role of an aged immune system. Ageing Res Rev. 2017 Jul;36:1-10. doi: 10.1016/j.arr.2017.01.006. Epub 2017 Feb 20.
Wong CH, Weiss D, Sourial N, Karunananthan S, Quail JM, Wolfson C, Bergman H
Frailty and its association with disability and comorbidity in a community-dwelling sample of seniors in Montreal: a cross-sectional study. Aging Clin Exp Res. 2010 Feb;22(1):54

Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial

Details for clinical trial NCT03633279

Clinical trial NCT03633279 - References